Enlil Expands AI-Powered Traceability Platform in MedTech

Enlil, Inc. has announced growing momentum for its AI-powered development traceability platform across the global MedTech ecosystem, as stated in a press release. Since appointing Nader Fathi as CEO in February, the company has expanded its reach among OEMs, contract manufacturers, and industry partners, now boasting over 600 users worldwide.

The platform integrates AI-powered intelligence, including a private large language model-driven chatbot named Ask Lily, which provides rapid insights to engineering, quality, and regulatory teams. This allows for smarter decision-making without compromising sensitive intellectual property or compliance integrity.

Enlil's platform is designed to overcome challenges associated with fragmented technology stacks and siloed documentation, offering end-to-end traceability and secure cross-functional collaboration. It integrates key product development disciplines such as Requirements Management, QMS, PLM, Manufacturing, ERP, Regulatory Compliance, and Post-Market Surveillance into a unified digital thread.

Shifamed, the innovation network backing Enlil, supports the platform's expansion with advanced AI capabilities, establishing it as a leading solution for regulated product development in the MedTech sector.